Professor Sue Ann Costa Clemens CBE, Chair of Global Health at the Department of Paediatrics and Head of Oxford Latam Research Group \u2013 a collaboration between Oxford and Brazil, aimed at strengthening our commitment to global health \u2013 met with His Excellency Antonio Patriota, Brazilian Ambassador to the UK, to discuss the co-development of a Malaria vaccine and advance public health outcomes in Brazil.
Scientists at the University of Oxford and the University of Edinburgh have launched a pioneering study that examines how the immune system responds to repeated malaria infections. The BIO-004 study is being run in partnership between the Department of Biochemistry (Draper Lab, based in the Kavli Institute for Nanoscience Discovery), the University of Edinburgh (Spence Lab, Institute of Immunology and Infection Research) and the Oxford Vaccine Group (part of the Department of Paediatrics). BIO-004 will provide a unique insight into how the immune system adapts over the first few malaria infections of life, learning to tolerate malaria parasites and developing natural immunity to severe illness.
The Department of Paediatrics at the University of Oxford, has entered into an agreement with three Brazilian Universities, to contribute to the delivery of an undergraduate course in \u2018Translational Science\u2019, starting in 2024.
Researchers from the Department of Paediatrics today welcomed the Rt Hon Andrew Mitchell MP, Minister for Development and Africa, to the laboratories and clinics of several of its vaccine development groups.
Oxford Vaccine Group (OVG), which led the rapid clinical development of the Oxford vaccine in COVID-19 in the pandemic, has been awarded a total of \u00a37,788,783 by UK Aid for research into the prevention of five dangerous diseases with epidemic or pandemic potential.
Experts have launched a new campaign in a bid to boost waning vaccine uptake by giving people more information about how clinical trials work. Researchers hope to alleviate hesitancy by showing with a simple animation and comic the complex way vaccines are developed.
Experts linked to the International Pandemic Preparedness Secretariat (IPPS) visited the University of Oxford\u2019s vaccine laboratories this week as part of a two-day gathering on accelerating pandemic preparedness.
The University of Oxford and the Coalition for Epidemic Preparedness Innovations (CEPI) today announced the launch of a new project to initiate early development of prototype vaccines against the Jun\u00edn virus, selected as an exemplar of the Arenavirus family which is responsible for multiple deadly haemorrhagic fevers with epidemic and pandemic potential.
A pioneering study into human immunity is being launched today by Oxford Vaccine Group at the University of Oxford. The study, called LEGACY03, is being funded by the Medical Research Council part of UK Research and Innovation. By investigating how lymph nodes work, and how they make responses to vaccines in younger and older people, it has the potential to improve vaccine design for different age groups significantly.
Researchers at the University of Oxford's Pandemic Sciences Institute have launched a new clinical trial to find a vaccine to protect people against Middle East Respiratory Syndrome (MERS).
A University of Oxford study has administered a new vaccine against tick-borne virus Crimean-Congo haemorrhagic fever (CCHF) to human volunteers for the first time. The clinical trial of the ChAdOx2 CCHF vaccine aims to confirm its safety and understand how individuals develop immunity following vaccination.
The University of Oxford and the Coalition for Epidemic Preparedness Innovations (CEPI) have entered into a strategic partnership to accelerate the development of safe, effective and globally accessible vaccines to counter the threat of future pandemics.
Up to $30 million in funding has been announced by the Coalition for Epidemic Preparedness Innovations (CEPI) to bring a new nanoparticle vaccine offering protection against a range of coronaviruses to clinical trial.
COVID-19 vaccines given as fourth doses in the UK offer excellent boosting immunity protection, according to the latest results from a nationwide NIHR-supported study.
The University of Oxford in collaboration with the University of Maryland School of Medicine (UMSoM) has begun recruiting for a Phase I/II trial of a new paratyphoid vaccine in human volunteers in Oxford.
The Oxford Vaccine Group\u2019s Lead Statistician, Professor Merryn Voysey, received the prestigious Australian of the Year in the UK award at a gala dinner recently.
The University of Oxford and Brazilian Ministry of Health have announced a joint initiative to set up a global health and clinical research unit in Brazil led by Professor Sue Ann Clemens CBE.
![\"\"](\"https://www.paediatrics.ox.ac.uk/news/advancing-a-malaria-vaccine-for-better-global-health-outcomes/responsive_image?ratio=r16x9&scale=w760\")
\n \n \n\n\n